Karyopharm Therapeutics Inc.
Simbol: KPTI
NASDAQ
1.37
USDPrețul de piață astăzi
-0.9064
Raportul P/E
-0.0160
Raportul PEG
157.64M
MRK Cap
- 0.00%
Randament DIV
Karyopharm Therapeutics Inc. (KPTI) Situații financiare
Bilanț
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 897.57 | 192.1 | 278 | 228.6 | |||||||||||||
balance-sheet.row.short-term-investments | 636.07 | 139.2 | 142.8 | 38.2 | |||||||||||||
balance-sheet.row.net-receivables | 132.37 | 27 | 47.1 | 22.5 | |||||||||||||
balance-sheet.row.inventory | 13.65 | 3 | 4.2 | 4.1 | |||||||||||||
balance-sheet.row.other-current-assets | 226.73 | 11.8 | 19.8 | 2.9 | |||||||||||||
balance-sheet.row.total-current-assets | 1069.53 | 233.9 | 326.8 | 258.1 | |||||||||||||
balance-sheet.row.property-plant-equipment-net | 23.05 | 4.9 | 7.4 | 1.6 | |||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.long-term-investments | 1.7 | 0.3 | 0.6 | 0.6 | |||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.other-non-current-assets | 39.74 | 1.3 | 23.4 | 44.9 | |||||||||||||
balance-sheet.row.total-non-current-assets | 64.5 | 6.5 | 31.4 | 47.2 | |||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-assets | 1134.03 | 240.4 | 358.2 | 305.3 | |||||||||||||
balance-sheet.row.account-payables | 15.4 | 3.1 | 2.8 | 1.6 | |||||||||||||
balance-sheet.row.short-term-debt | 12.56 | 3.3 | 2.9 | 2.3 | |||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.long-term-debt-total | 686.92 | 170.9 | 170.1 | 169.3 | |||||||||||||
Deferred Revenue Non Current | 530.39 | 132.5 | 132.7 | 133 | |||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -395.13 | - | - | - | |||||||||||||
balance-sheet.row.other-current-liab | 172.27 | 63 | 60.3 | 0.7 | |||||||||||||
balance-sheet.row.total-non-current-liabilities | 1358.64 | 307.2 | 374.8 | 385 | |||||||||||||
balance-sheet.row.other-liabilities | -123.63 | 0 | -65.9 | -73.7 | |||||||||||||
balance-sheet.row.capital-lease-obligations | 25.52 | 2.8 | 9 | 11.3 | |||||||||||||
balance-sheet.row.total-liab | 1487.05 | 376.6 | 374.8 | 385 | |||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.common-stock | 0.05 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.retained-earnings | -5721 | -1487 | -1343.9 | -1178.6 | |||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -2.1 | -0.2 | -0.6 | 0.2 | |||||||||||||
balance-sheet.row.other-total-stockholders-equity | 5370.03 | 1351 | 1327.9 | 1098.8 | |||||||||||||
balance-sheet.row.total-stockholders-equity | -353.02 | -136.2 | -16.7 | -79.7 | |||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 1134.03 | 240.4 | 358.2 | 305.3 | |||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-equity | -353.02 | -136.2 | -16.7 | -79.7 | |||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 1134.03 | - | - | - | |||||||||||||
Total Investments | 636.37 | 139.5 | 142.8 | 38.2 | |||||||||||||
balance-sheet.row.total-debt | 696.11 | 177 | 173 | 169.3 | |||||||||||||
balance-sheet.row.net-debt | 434.6 | 124.1 | 37.8 | -21.2 |
Situația fluxurilor de numerar
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -143.1 | -143.1 | -165.3 | -124.1 | |||||||||||||
cash-flows.row.depreciation-and-amortization | 0.53 | 0.5 | 0.6 | 0.8 | |||||||||||||
cash-flows.row.deferred-income-tax | 5.92 | -1.1 | 0 | 1.5 | |||||||||||||
cash-flows.row.stock-based-compensation | 21.71 | 21.7 | 35.4 | 29.8 | |||||||||||||
cash-flows.row.change-in-working-capital | 31.41 | 31.4 | -20 | -23.2 | |||||||||||||
cash-flows.row.account-receivables | 20.12 | 20.1 | -5.1 | -9.6 | |||||||||||||
cash-flows.row.inventory | 1.18 | 1.2 | -0.1 | -1.5 | |||||||||||||
cash-flows.row.account-payables | 0.35 | 0.3 | 1.2 | -2.8 | |||||||||||||
cash-flows.row.other-working-capital | -0.7 | 9.8 | -16 | -9.3 | |||||||||||||
cash-flows.row.other-non-cash-items | -9.19 | -2.2 | -0.3 | 8.1 | |||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -92.72 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.1 | -5.7 | |||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 104.3 | 5.5 | |||||||||||||
cash-flows.row.purchases-of-investments | -159.15 | -159.2 | -226 | -45.2 | |||||||||||||
cash-flows.row.sales-maturities-of-investments | 167.09 | 167.1 | 121.9 | 192.8 | |||||||||||||
cash-flows.row.other-investing-activites | -18.9 | 0 | -104.3 | -5.5 | |||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 7.94 | 7.9 | -104.3 | 141.8 | |||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | -60 | |||||||||||||
cash-flows.row.common-stock-issued | 1.12 | 1.1 | 189.8 | 9.9 | |||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.other-financing-activites | 1.12 | 1.1 | 4 | 123.7 | |||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 39.69 | 1.1 | 193.7 | 73.6 | |||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.03 | 0 | -0.5 | 0 | |||||||||||||
cash-flows.row.net-change-in-cash | -83.61 | -83.4 | -60.6 | 108.3 | |||||||||||||
cash-flows.row.cash-at-end-of-period | 264.86 | 52.9 | 136.9 | 197.4 | |||||||||||||
cash-flows.row.cash-at-beginning-of-period | 348.48 | 136.3 | 197.4 | 89.1 | |||||||||||||
cash-flows.row.operating-cash-flow | -92.72 | -92.7 | -149.6 | -107.1 | |||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.1 | -5.7 | |||||||||||||
cash-flows.row.free-cash-flow | -92.72 | -92.7 | -149.7 | -112.8 |
Rândul din contul de profit și pierdere
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 146.03 | 146 | 157.1 | 209.8 | |||||||||||||
income-statement-row.row.cost-of-revenue | 5.02 | 5.5 | 5.2 | 3.4 | |||||||||||||
income-statement-row.row.gross-profit | 141.01 | 140.6 | 151.9 | 206.4 | |||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||
income-statement-row.row.research-development | 138.67 | - | - | - | |||||||||||||
income-statement-row.row.selling-general-administrative | 131.88 | - | - | - | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-expenses | -0.36 | -0.4 | -0.1 | -0.1 | |||||||||||||
income-statement-row.row.operating-expenses | 270.55 | 270.1 | 294.1 | 304.7 | |||||||||||||
income-statement-row.row.cost-and-expenses | 275.57 | 275.6 | 299.3 | 308.1 | |||||||||||||
income-statement-row.row.interest-income | 10.94 | 10.9 | 2.4 | 0.6 | |||||||||||||
income-statement-row.row.interest-expense | 23.82 | 23.8 | 25 | 26 | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.total-other-income-expensenet | -6.95 | -13.2 | -22.7 | -25.5 | |||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-operating-expenses | -0.36 | -0.4 | -0.1 | -0.1 | |||||||||||||
income-statement-row.row.total-operating-expenses | -6.95 | -13.2 | -22.7 | -25.5 | |||||||||||||
income-statement-row.row.interest-expense | 23.82 | 23.8 | 25 | 26 | |||||||||||||
income-statement-row.row.depreciation-and-amortization | 5.58 | 0.5 | 2.3 | 0.5 | |||||||||||||
income-statement-row.row.ebitda-caps | -121.1 | - | - | - | |||||||||||||
income-statement-row.row.operating-income | -129.54 | -129.5 | -142.2 | -98.3 | |||||||||||||
income-statement-row.row.income-before-tax | -142.78 | -142.8 | -164.9 | -123.8 | |||||||||||||
income-statement-row.row.income-tax-expense | 0.32 | 0.3 | 0.4 | 0.3 | |||||||||||||
income-statement-row.row.net-income | -143.1 | -143.1 | -165.3 | -124.1 |
Întrebări frecvente
Ce este Karyopharm Therapeutics Inc. (KPTI) totalul activelor?
Karyopharm Therapeutics Inc. (KPTI) activele totale sunt 240438000.000.
Care este venitul anual al întreprinderii?
Venitul anual este 69756000.000.
Care este marja de profit a întreprinderii?
Marja de profit a firmei este 0.966.
Care este fluxul de numerar liber al întreprinderii?
Fluxul de numerar liber este -0.808.
Care este marja de profit net a întreprinderii?
Marja profitului net este -0.980.
Care este venitul total al întreprinderii?
Venitul total este -0.887.
Care este Karyopharm Therapeutics Inc. (KPTI) profitul net (venitul net)?
Profitul net (venitul net) este -143099000.000.
Care este datoria totală a firmei?
Datoria totală este 177016000.000.
Care este numărul cheltuielilor de exploatare?
Cheltuielile de exploatare sunt 270101000.000.
Care este cifra de numerar a firmei?
Numerarul întreprinderii este 52891000.000.